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Background: To confirm whether clinical and biochemical parameters or Hashimoto’s thyroiditis (HT) could predict
the risks of malignancy among subjects who underwent thyroidectomy, as well as to determine the influence of HT
on the biological behavior of papillary thyroid cancer (PTC).
Methods: A total of 2,052 patients who underwent initial thyroidectomy were enrolled between June 2006 and
August 2008. Serum free T4, free T3, thyrotropin (TSH), thyroglobulin, thyroglobulin antibody, antimicrosomal
antibody, tumor-associated status, and thyroid disorders were documented.
Results: Binary logistic regression analysis was performed to define the risk predictors for thyroid cancer. Finally,
calcification, HT, TSH, and age, were entered into the multivariate model. Multivariate logistic regression analysis revealed
the risk of thyroid cancer increases in parallel with TSH concentration within normal range, and the risk for malignancy
significantly increased with serum TSH 1.97–4.94 mIU/L, compared with TSH less than 0.35 mIU/L (OR = 1.951, 95%
CI = 1.201–3.171, P = 0.007). Increased risks of thyroid cancer were also detected among the patients with HT (OR = 3.732,
95% CI = 2.563–5.435), and microcalcification (OR = 14.486, 95% CI = 11.374–18.449). The effects of HT on the
aggressiveness of PTC were not observed in extrathyroidal invasion (P = 0.347), capsular infiltration (P = 0.345),
angioinvasion (P = 0.512), and lymph node metastases (P = 0.634).
Conclusions: The risk of malignancy increases in patients with higher level TSH within normal range, as well as the
presence of HT and microcalcification. No evidence suggests that coexistent HT alleviates the aggressiveness of PTC.
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Thyroid cancer is the most frequent endocrine malignancy,
accounting for approximately 1% of all malignant tumors
in the United States [1]. However, a recent study [2] by the
Office of Cancer Prevention and Treatment indicates that
thyroid cancer represents 5.90% of all new malignant
diseases in one district of Wenzhou (a coastal city in
Southeast China, with a referral population of 7,558,000).
The detection rate of thyroid nodules is higher than before
because of high-resolution ultrasound [3]. In order to iden-
tify patients with thyroid cancer who require early inter-
vention, many predisposing factors for malignancy have* Correspondence: zhangxiaohua577@hotmail.com
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reproduction in any medium, provided the orbeen recognized, including young age (<20 years old) or
older age (>70 years old), male gender, large (>4 cm) or
rapidly growing nodules, and history of radiation exposure,
calcification and thyroglobulin (Tg) [4-7]. The role of
thyroid-stimulating hormone (TSH) in the growth and de-
velopment of thyroid cancer has long been known [8]. Re-
cently, Boelaert et al. [9] proposed that the TSH level at
presentation is a novel predictor of malignancy in patients
with thyroid nodules. Another report indicated that higher
TSH levels were associated with greater risks of differenti-
ated thyroid cancer and advanced tumor stage [10]. The
findings above need to be verified further.
Hashimoto’s thyroiditis (HT) is an autoimmune dis-
ease characterized by widespread lymphocyte infiltration,
fibrosis, and parenchymal atrophy [11]. Historically, HT
was thought to be associated with malignant lymphoma.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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association between HT and papillary thyroid cancer
(PTC) [12]. The coexistence of these two diseases has
been variously reported to range from 0.5% to 38.0%
[11,13-18]. A few studies have proposed HT as a risk fac-
tor for thyroid cancer [12,16,18,19], whereas others have
reported a negative correlation between the two diseases
[10,13,15]. Nowadays, the causal association between
these diseases remains controversial, and few papers
have discussed whether HT influences the clinical and
pathologic features of thyroid cancer.
Therefore, the current study investigates which clinical
features or biochemical criteria predict the likelihood of
thyroid malignancy in patients with thyroid nodules,
thereby identifying those at greatest risk of harboring
thyroid cancer. Other objectives of the current study are
to determine the following: 1) the relative incidence of
HT and PTC among patients undergoing thyroidectomy,
and 2) the possible influence of HT on the clinical be-
havior and neoplastic aggressiveness of PTC.
Methods
A total of 2,052 patients (1,645 female and 407 male) with
thyroid nodules, in whom malignancy was suspected
under fine-needle aspiration (FNA) or ultrasonography, or
who had rapidly growing nodules or nodules fixed to adja-
cent structures, and who underwent initial thyroidectomy
in the First Affiliated Hospital of Wenzhou Medical
College, were retrospectively recruited from June 2006 to
August 2008. However, some female patients underwent
surgery because of cosmetic problems or anxiety about
the effects on their quality of life. The majority of the pa-
tients received treatment for thyroid cancer according to
the accepted protocol, which involves total or near-total
thyroidectomy, followed by thyroid hormone suppression.
Cervical lymph node dissection or sentinel lymph node bi-
opsy was performed routinely during thyroid cancer’s
operation. Others underwent resection of the whole or
partial lobes of the thyroid gland.
The diagnosis was confirmed either on reevaluation of
histopathology sections when available, or on reviewing the
previous pathology reports. The histologic type of thyroid
cancer was assessed by two senior pathologists according
to the World Health Organization criteria and classified
as PTC in 1004 patients (98.05%), including two with
coexisting PTC and malignant lymphoma, follicular thy-
roid cancer (FTC) in four patients (0.39%), medullary
thyroid cancer in twelve patients (1.17%), and anaplastic
thyroid cancer in four patients (0.39%). Patients who were
characterized by the presence of diffuse lymphocytic and
plasma cell infiltration, oxyphilic cells, and lymphoid folli-
cles with reactive germinal centers, were defined as having
HT. Whereas patients with lymphocytic infiltration imme-
diately surrounding the malignant tumor (but withoutother lobe involvement) were considered as having thyroid
cancer alone because the surrounding inflammation may
represent an immune response to the host tumor [20].
In addition to the demographic data (age and gender),
data on the thyroid-associated parameters [serum free
T4 (fT4), free T3 (fT3), TSH, Tg, and thyroglobulin anti-
body (TgAb), antimicrosomal antibody (TMAb)], tumor-
associated status (tumor size, number and region of
positive lymph nodes, and metastasis (TNM) stage), and
thyroid disorders (presence or absence of HT, Graves
disease, follicular adenoma, or malignant lymphoma)
were obtained from a review of the medical records from
the Patient Information Inquiry System. The normal
ranges of serum fT3, fT4, TSH, Tg, TgAb, and TMAb
were 3.67 to 10.43 pmol/L, 7.5 to 21.1 pmol/L, 0.35 to
4.94 mIU/L, 4.14 to 14.46 ng/ml, 0.0% to 30.0%, and
0.0% to 20.0%, respectively. We had free thyroid hor-
mones, TSH, Tg, TgAb, and TMAb measured simultan-
eously with surgery. However, the measurement results
of patients known to have taken thyroid medication
were excluded. This research was approved by the Ethics
Committee of the First Affiliated Hospital of Wenzhou
Medical College.
The final diagnostic outcome was defined as the pres-
ence or absence of thyroid cancer. Data were analyzed
using Statistical Package for Social Science (SPSS) version
13.0. The odds ratio (OR) in multivariate logistic regres-
sion analysis, with the relative 95% CI was calculated to
assess the relevance of thyroid-associated clinical or bio-
chemical conditions to predict the final diagnostic out-
come. Confounding factors, including age, gender, and
thyroid disorders, were investigated statistically. Compari-
sons of frequency distributions and numerical variable
data were performed using the chi-square (χ2) test. Ob-
served differences were considered statistically significant
if the probability of chance occurrence was less than 0.05.
Results
The clinical and biochemical features of patients with and
without thyroid cancer were compared. Of the 1,024 pa-
tients with thyroid cancer, female patients (n = 843)
accounted for the majority (female/male ratio = 4.66/
1.00). The age distribution (range 10 to 84 years, mean
45.0 ± SD 12.1 years) revealed a predominance in the 30
to 44-year-old age group (n = 449 patients, 43.8%) with
thyroid cancer. However, the high tumor incidence in the
45 to 60-year-old age group (n = 370 patients, 36.1%)
should not be neglected. Comparison between the two
groups highlighted a statistically significant difference in
gender (χ2 = 5.990, P = 0.014), age (χ2 = 13.588, P = 0.018)
(Table 1). To avoid the interference of several extreme
values, fT3, fT4, TSH, Tg, TgAb, and TMAb were treated
as categorical variables in the analysis. Significant differ-
ences were detected when the following values were
Table 2 Comparison of the biochemical features of
patients with and without thyroid cancer





The level of thyroid-associated
hormone
fT3, pmol/Lb 0.306
<3.67 82 (9.2) 66 (7.3)
3.67 to 4.42 263 (29.6) 287 (31.7)
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P <0.001) and TMAb (χ2 = 15.026, P <0.001) but not fT3
(χ2 = 4.784, P = 0.306), fT4 (χ2 = 4.548, P = 0.337), and Tg
(χ2 = 3.431, P = 0.180) among patients with and without
thyroid cancer (Table 2). Moreover, the presence of HT was
associated with thyroid cancer (χ2 = 67.421, P <0.001). Re-
garding calcification of the thyroid nodules, the incidence
of microcalcification was higher in patients with thyroid
cancer than in the controls (71.4% vs 16.2%, χ2 = 633.792,
P <0.001). However, the prevalence of thyroid cancer was
similar in patients with solitary nodules and patients with
multiple nodules (χ2 = 1.456, P = 0.228) (Table 1).
Subsequently, a binary logistic regression analysis was
performed to define the risk predictors for thyroid can-
cer, which simultaneously analyzed gender, age, serum
fT3, fT4 and TSH concentration, HT, and calcification.
In addition, considering the feedback inhibition regula-
tion of TSH by serum fT3 and fT4 concentrations, the
interaction of variables between TSH and/or fT3, and/or
fT4 were also taken into account in the analysis. Finally,
four variables, namely, calcification, HT, TSH, and age,Table 1 Comparison of characteristics of patients with
and without thyroid cancer






Male 181 (17.7) 226 (22.0)
Female 843 (82.3) 802 (78.0)
Age, yr 0.018*
0 ~ 14 3 (0.3) 5 (0.5)
15~29 85 (8.3) 89 (8.7)
30~44 449 (43.8) 382 (37.2)
45~59 370 (36.1) 411 (40.0)
60~74 103 (10.1) 133 (12.9)
75~89 14 (1.4) 8 (0.8)
Nodular type 0.228
Diffuse/multinodular goiter 651 (63.6) 627 (61.0)
Solitary nodules 373 (36.4) 401 (39.0)
Calcification
Coarse calcifications 0.727
Absent 886 (86.5) 884 (86.0)
Present 138 (13.5) 144 (14.0)
Microcalcification <0.001*
Absent 293 (28.6) 861 (83.8)
Present 731 (71.4) 167 (16.2)
HT <0.001*
Absent 836 (81.6) 962 (93.6)
Present 188 (18.4) 66 (6.4)
Results are presented as number (%) of patients. aCalculated using chi-square
test; *statistically significant (P <0.05). HT, Hashimoto’s thyroiditis.were entered into the multivariate model via forward
stepwise regression (likelihood ratio). An increased risk of
thyroid cancer was detected among the patients with HT
(OR = 3.732, 95%CI = 2.563–5.435), microcalcification
(OR = 14.486, 95%CI = 11.374–18.449). There was signifi-
cantly increased risk of malignancy in patients with serum
TSH of 1.97 to 4.94 mIU/L, compared to patients with
TSH below 0.35 mIU/L (OR = 1.951, 95% CI = 1.201–
3.171, P = 0.007) (Table 3).4.43 to 4.97 284 (32.0) 266 (29.4)
4.98 to 10.43 258 (29.1) 283 (31.3)
>10.43 1 (0.1) 2 (0.2)
fT4, pmol/Lb 0.337
<7.5 11 (1.2) 5 (0.6)
7.5 to 12.83 301 (33.9) 282 (31.2)
12.84 to 14.85 281 (31.6) 303 (33.5)
14.86 to 21.1 283 (31.9) 299 (33.0)
>21.1 12 (1.4) 16 (1.8)
TSH, mIU/Lb <0.001*
<0.35 58 (6.1) 84 (8.7)
0.35 to 1.17 258 (27.1) 312 (32.4)
1.18 to 1.96 273 (28.6) 283 (29.4)
1.97 to 4.94 317 (33.3) 247 (25.7)
>4.94 47 (4.9) 36 (3.7)
Tg, ng/ml 0.180
<4.14 131 (34.3) 107 (36.1)
4.14 to 14.46 158 (41.4) 103 (34.8)
>14.46 93 (24.3) 86 (29.1)
Antibodyc (n = 748)
TgAb <0.001*
Negative 309 (78.4) 314 (88.7)
Positive 85 (21.6) 40 (11.3)
TMAb <0.001*
Negative 309 (78.4) 315 (89.0)
Positive 85 (21.6) 39 (11.0)
Results are presented as number (%) of patients. aCalculated using chi-square
test; bpatients with free T3 (fT3), fT4, or thyroid-stimulating hormone (TSH)
measurements within the normal range were divided into three tertiles of
similar size, respectively; conly 748 patients who had information on
thyroglobulin antibody (TGAb) and antimicrosomal antibody (TMAb) were
included in the analysis; *statistically significant (P <0.05). Tg, thyroglobulin.
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were selected and divided into patients with HT (group I)
and patients without HT (group II) based on the final
histologic examination. Tables 4 and 5 show the clinical
and pathologic features of the two groups; 18.63% of the
patients with PTC had concurrent HT, which was more
frequent than in the benign group (P <0.001). Moreover,
the female patients constituted an overwhelming 97.3%
(n = 182) of the patients with coexisting PTC and HT.
The mean age at initial thyroidectomy was similar be-
tween the groups (χ2 = 7.298, P = 0.063), as well as
thyroid-associated disorders (χ2 = 3.322, P = 0.325)
(Table 4). Furthermore, the tumor size (χ2 = 2.975, P =
0.209), frequency of occult PTC (χ2 = 2.872, P = 0.090),
extrathyroidal invasion (χ2 = 0.885, P = 0.347), capsular in-
filtration (χ2 = 0.891, P = 0.345), angioinvasion (χ2 =
0.429, P = 0.512), and lymph node metastases (χ2 = 0.227,
P = 0.634) did not differ between patients with and with-
out HT. No distant metastasis was observed in the two
groups. Although the majority of positive lymph nodes
(58.3%) in patients with HT were distributed in level VI
(classification references [21]) and a higher proportion
was observed in group I with stage I (85.6%), the differ-
ence was not significant compared with group II (χ2 =
4.703, P = 0.427; χ2 = 0.540, P = 0.910, respectively), inTable 3 Independent risk predictors for diagnosis of
thyroid malignancy under multivariate logistic regression
analysis (n = 1,789 patients)
Variable Adjusted odds ratio 95% CI P-value
Age, yr 0.004*
0 ~ 14 1.00
15~29 1.217 0.164, 9.032 0.848
30~44 1.544 0.215, 11.092 0.666
45~59 1.188 0.165, 8.550 0.864
60~74 0.724 0.098, 5.321 0.751
75~89 2.852 0.300, 27.138 0.362
TSH, mIU/La 0.001*
<0.35 1.00
0.35 to 1.17 1.079 0.663, 1.756 0.759
1.18 to 1.96 1.357 0.835, 2.207 0.218
1.97 to 4.94 1.951 1.201, 3.171 0.007*
>4.94 1.235 0.598, 2.550 0.568
HT
Absent 1.00
Present 3.732 2.563, 5.435 <0.001*
Calcification
Coarsecalcifications 1.00
Microcalcification 14.486 11.374, 18.449 <0.001*
aPatients with free T3 (fT3), fT4, or TSH measurements within the normal range
were divided into tertiles of similar size, respectively. Variables assigned odds
ratios of 1.0 were used as the reference for multivariate analysis. *Statistically
significant (P <0.05).other words, the pathologic TNM (pTNM) classifica-
tion in the two groups were similar (shown in Table 5).Discussion
As shown in the current study, the peak incidence of thy-
roid cancer in Wenzhou occurs in the 30 to 44-year-old
age group. Moreover, when the association between gen-
der and thyroid cancer was assessed, significantly in-
creased rates of malignancy were detected among the
female patients (82.3%) (χ2 = 5.990, P = 0.014). However,
further logistic regression analysis did not identify gender
as an independent risk predictor. These results may chal-
lenge a previously recognized view of an increased risk of
underlying malignancies in male patients [5,9,22,23]. Fur-
thermore, the patient age was demonstrated as a risk pre-
dictor for malignancy. Increased adjusted ORs for thyroid
cancer were observed in the older age group (75 years) in
accordance with previous reports [22,24], although no sig-
nificant difference was observed compared with the young
age group (<15 years, P = 0.362).
The risk of thyroid cancer has been shown to increase
with serum TSH concentrations, and even within normal
ranges, higher TSH levels are associated with a higher in-
cidence and more advanced stage of thyroid malignant
tumor [9,10,24,25]. Serum TSH has a tropic effect on thy-
roid nodules and suppression of TSH concentration by ad-
ministration of exogenous thyroxine may interfere with
the growth of established nodules, as well as the formation
of new thyroid nodules [26-29]. TSH suppression is also
associated with a decreased frequency of PTC [30].Table 4 Clinical features of patients with papillary thyroid
cancer by group in patients with and without
Hashimoto’s thyroiditis (HT)
Characteristics Group I Group II χ2 P-
value(with HT) (without HT)
n = 187 n = 817
Age, yr 7.298 0.063
<30 23 (12.3) 65 (8.0)
30~44 76 (40.6) 362 (44.3)
45~59 74 (39.6) 291 (35.6)
>60 14 (7.5) 99 (12.1)
Gender 35.082 <0.001*
Male 5 (2.7) 171 (20.9)
Female 182 (97.3) 646 (79.1)
Thyroid-associated disorders 3.322 0.325
Nodular goiter 56 (81.2) 258 (82.2)
Follicular adenoma 8 (11.6) 45 (14.3)
Graves disease 4 (5.8) 10 (3.2)
Malignant lymphoma 1 (1.4) 1 (0.3)
Results are presented as number (%) of patients. *Statistically significant
(P < 0.05).
Table 5 Pathologic features of patients with papillary
thyroid cancer (PTC) by group in patients with and
without Hashimoto’s thyroiditis (HT)
Characteristics Group I Group II χ2 P-
value
(with HT) (without HT)
n = 187 n = 817
Pathological TNM staging 0.540 0.910
I 160 (85.6) 687 (84.1)
II 4 (2.1) 25 (3.1)
III 15 (8.0) 70 (8.6)
IV 8 (4.3) 35 (4.3)
Tumor size 2.975 0.209
≤1 cm 126 (67.4) 496 (60.7)
1 to 4 cm 59 (31.6) 304 (37.2)
>4 cm 2 (1.1) 17 (2.1)
Frequency of occult PTC 2.872 0.090
Absent 61 (32.6) 321(39.3)
Present 126 (67.4) 496 (60.7)
Lymph nodes metastases 0.227 0.634
Absent 129 (69.0) 578 (70.7)
Present 58 (31.0) 239 (29.3)
Distribution of positive lymph
nodes
4.703 0.427
Level VI 49 (58.3) 217 (54.5)
Level II 9 (10.7) 33 (8.3)
Level III 9 (10.7) 48 (12.1)
Level IV 10 (11.9) 47 (11.8)
Level V 6 (7.1) 52 (13.1)
Level I 1 (1.2) 1 (0.3)
Extrathyroidal invasion 0.885 0.347
Absent 184 (98.4) 794 (97.2)
Present 3 (1.6) 23 (2.8)
Capsular infiltration 0.891 0.345
Absent 159 (85.0) 671 (82.1)
Present 28 (15.0) 146 (17.9)
Vascular invasion 0.429 0.512
Absent 186 (99.5) 815 (99.8)
Present 1 (0.5) 2 (0.2)
Distant metastases 0 0
Results for Groups I and II are presented as number (%) of patients.
*Statistically significant (P <0.05).
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creased in parallel with the serum TSH concentration
within the normal range at presentation. This observa-
tion is supported by a previous study [24]. In our study,
serum TSH concentration (>4.94 mIU/L) was not associ-
ated with the greatest risk of thyroid cancer, which is in-
consistent with other studies [8,9]. We have no vigorous
explanation for this inconsistency. One reason may bethat the sample size of the group with serum TSH con-
centrations >4.94 mIU/L was smaller than the other
groups. In addition, the mechanism of TSH on thyroid
disease may differ between populations. Furthermore,
several arguments weaken the role of TSH in the devel-
opment or progression of malignant thyroid tumors: 1)
TSH receptor mutations in regions functionally associ-
ated with increased signal transduction do not often
occur in malignant thyroid tumors [31]; 2) other growth
factors such as insulin-like growth factor-I (IGF-I) have
been demonstrated to have a more important role in the
growth of thyroid cancer in in vitro studies [32,33], and
TSH needs cooperation with insulin/IGF-1 to educe its
proliferative effects [34]; 3) Shi et al. [35] reported that
the relationship between TSH receptor mRNA levels
and the aggressiveness of cancer was inversed; 4) thyroid
cancer occurs in patients with serum TSH concentra-
tions suppressed by hyperfunctioning nodules in the
contralateral lobe [36]; 5) a recent study showed that pa-
tients carrying one of two alleles associated with an in-
creased risk of differentiated thyroid cancer have lower
serum TSH concentrations [37].
Taken together, TSH is unlikely to act versatilely in
cancer development. These findings indicate that serum
TSH concentration can be used as an adjunct biochem-
ical predictor of thyroid cancer. However, this requires
further investigation.
In contrast to previous studies [7,38] that reported
that Tg levels were significantly higher in patients with
thyroid cancer than in those with benign disorders, no
significant difference in Tg concentration was observed
in patients with malignancy. Limited to the current
measurement, whether preoperative serum Tg measure-
ment helps differentiate benign from malignant thyroid
disorders needs further verification. Ultrasonography
cannot reliably distinguish benign from malignant le-
sions [39]. The current study demonstrates similar inci-
dences of malignancy between patients with solitary
nodules and those with diffuse or multinodular lesions,
as reported by ultrasonography, although others found
that the presence of solitary nodules found by palpation
is associated with increased malignancy rates [5,9,40,41].
In addition, a higher risk of malignancy was detected in
patients with microcalcification (OR = 14.486, P <0.001,
Table 3), which is consistent with recent investigations
in patients evaluated through ultrasonography [42,43].
Nevertheless, approximately 13.5% of patients with thyroid
cancer (n = 138) were confirmed to have coexisting coarse
calcifications. Accordingly, ultrasonographic findings, such
as solitary nodules or multinodular types, as well as
microcalcifications or coarse calcifications, should not pre-
vent further evaluation of benign or malignant lesions.
In the present study, a vast majority of thyroid malig-
nancies were PTC (98.05%) and HT was found to
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regression analysis identified the presence of HT as an
independent risk predictor for malignancy (OR = 3.732,
P <0.001, Table 3). These data confirm the large American
dataset from Dr. Skahen’s report of 1955 [12]. Subse-
quent studies showed a similar association between
PTC and HT. Although according to previous reports,
hypothyroidism induced by HT could induce high serum
TSH concentration, which may enhance the proliferative
activity of follicular epithelia and result in the develop-
ment of PTC [44], the oncogenic effect that causes PTC
in patients with HT are still unknown. According to
Harach et al. [45], iodine intake may play a role in the
tumorigenesis of thyroiditis. Although Wenzhou is an
iodine-sufficient area, determining the correlation between
HT and PTC in terms of iodine intake is difficult because
no information on iodine intake was available in the ma-
jority of patients studied. Some molecular mechanisms,
such as the PI3K/Akt or RET/RAS/ERK pathways may
also contribute to tumorigenesis [20,46]. At present,
no evidence suggests that HT is a premalignant lesion
for PTC. Furthermore, in contrast to previous studies
that reported that the presence of HT in PTC is associ-
ated with better prognosis, lower recurrence, and a less
aggressive disorder than cases without HT [47-49], the
current results did not find that HT has a protective
effect on tumor aggressiveness in patients with PTC,
which is consistent with the recent reports by Del Rio
et al. [50]. Recently, Kim et al. reported that HT was
positively associated with multifocality and smaller size
but not with extrathyroidal invasion, nodal metastasis,
or TNM stage [51]. These divergences may be due, at
least in part, to differences in patient selection (this
retrospective study only included patients undergoing
thyroidectomy, thus, a percentage of patients with HT
that are treated conservatively may have been omitted),
or to indications for thyroidectomy, inclusion of differ-
ent histologic types (others included PTC as well as
FTC), or varying definitions of thyroiditis. Nevertheless,
the current results indicate that the presence of HT rep-
resents an increased risk of developing thyroid cancer,
particularly PTC, but may have a minimum effect on
the aggressiveness of the malignancy.
Conclusions
In conclusion, the risk of thyroid malignancy increases
with the presence of HT and microcalcification as evalu-
ated by ultrasonography. Raised TSH levels within the
normal range are also independently associated with the
likelihood of thyroid malignancy. Coexisting HT in PTC
does not have a significant effect on the biologic behav-
ior of PTC. Based on the current findings, because the
study was retrospective, we do not advocate a more ag-
gressive role for surgical intervention for patients withHT, microcalcification, or even high TSH levels. Pro-
spective large-scale studies are required to verify or es-
tablish the potentially important factors for predicting
thyroid malignancy, and the follow-up of the patients
with HT in PTC should be done to verify long-term
prognosis in clinical practice.
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